Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43914
UPID:
TYOBP_HUMAN
Alternative names:
DNAX-activation protein 12; Killer-activating receptor-associated protein
Alternative UPACC:
O43914; A8K2X0; F5H389; Q6FGA5; Q9UMT3
Background:
TYRO protein tyrosine kinase-binding protein, also known as DNAX-activation protein 12 or Killer-activating receptor-associated protein, plays a pivotal role in immune cell signaling. It associates non-covalently with various activating receptors on immune cells, mediating cell activation upon ligand binding. TYROBP is crucial for neutrophil activation, myeloid cell activation, and NK cell receptor trafficking, enhancing immune responses.
Therapeutic significance:
Linked to Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, a disease characterized by presenile dementia and bone cysts, TYROBP's role in this condition underscores its potential as a therapeutic target. Understanding the role of TYRO protein tyrosine kinase-binding protein could open doors to potential therapeutic strategies.